Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 4
1955 3
1956 26
1957 39
1958 37
1959 31
1960 16
1961 22
1962 51
1963 37
1964 38
1965 28
1966 36
1967 31
1968 35
1969 29
1970 31
1971 57
1972 55
1973 76
1974 85
1975 101
1976 87
1977 78
1978 71
1979 101
1980 79
1981 77
1982 73
1983 83
1984 89
1985 82
1986 88
1987 73
1988 93
1989 93
1990 61
1991 94
1992 73
1993 88
1994 74
1995 90
1996 100
1997 108
1998 121
1999 151
2000 144
2001 170
2002 222
2003 204
2004 214
2005 265
2006 311
2007 364
2008 368
2009 384
2010 380
2011 402
2012 428
2013 488
2014 472
2015 419
2016 434
2017 445
2018 392
2019 385
2020 383
2021 95
Text availability
Article attribute
Article type
Publication date

Search Results

9,424 results
Results by year
Filters applied: . Clear all
Page 1
Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects.
Golmirzaei J, Mahboobi H, Yazdanparast M, Mushtaq G, Kamal MA, Hamzei E. Golmirzaei J, et al. Curr Pharm Des. 2016;22(5):590-4. doi: 10.2174/1381612822666151124235816. Curr Pharm Des. 2016. PMID: 26601963 Review.
Methylphenidate significantly reduces ADHD symptoms in children both at home and school and improves their social skills. Methylphenidate is safe in healthy children and has shown to have no cardiac side effects in these patients. ...
Methylphenidate significantly reduces ADHD symptoms in children both at home and school and improves their social skills. Methylph
Classics in Chemical Neuroscience: Methylphenidate.
Wenthur CJ. Wenthur CJ. ACS Chem Neurosci. 2016 Aug 17;7(8):1030-40. doi: 10.1021/acschemneuro.6b00199. Epub 2016 Jul 25. ACS Chem Neurosci. 2016. PMID: 27409720 Review.
As the first drug to see widespread use for the treatment of attention deficit hyperactivity disorder (ADHD), methylphenidate was the forerunner and catalyst to the modern era of rapidly increasing diagnosis, treatment, and medication development for this condition. ...In …
As the first drug to see widespread use for the treatment of attention deficit hyperactivity disorder (ADHD), methylphenidate was the …
Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Sugrue D, Bogner R, Ehret MJ. Sugrue D, et al. Am J Health Syst Pharm. 2014 Jul 15;71(14):1163-70. doi: 10.2146/ajhp130638. Am J Health Syst Pharm. 2014. PMID: 24973373 Review.
SUMMARY: The efficacy of methylphenidate in controlling ADHD symptoms is firmly established. Given the drug's relatively short half-life in pediatric patients (about 2.5 hours), a number of intermediate- and long-acting products have been developed; these extended-r …
SUMMARY: The efficacy of methylphenidate in controlling ADHD symptoms is firmly established. Given the drug's relatively short …
Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review.
Repantis D, Schlattmann P, Laisney O, Heuser I. Repantis D, et al. Pharmacol Res. 2010 Sep;62(3):187-206. doi: 10.1016/j.phrs.2010.04.002. Epub 2010 Apr 21. Pharmacol Res. 2010. PMID: 20416377 Review.
Of known interventions, psychopharmacology provides readily available options, such as methylphenidate and modafinil. Both drugs are presumed to be in widespread use as cognitive enhancers for non-medical reasons. ...Only studies with sufficient extractable data were inclu …
Of known interventions, psychopharmacology provides readily available options, such as methylphenidate and modafinil. Both drugs are …
Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.
Maldonado R. Maldonado R. Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1001-14. doi: 10.1517/17425255.2013.786041. Epub 2013 Apr 23. Expert Opin Drug Metab Toxicol. 2013. PMID: 23611637 Review.
INTRODUCTION: Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder of which the main features are inattention, hyperactivity and impulsivity. Methylphenidate (MPH) is the mainstay of treatment, but its short duration of action and consequent …
INTRODUCTION: Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder of which the main features are inattentio …
Pharmacokinetics and clinical effectiveness of methylphenidate.
Kimko HC, Cross JT, Abernethy DR. Kimko HC, et al. Clin Pharmacokinet. 1999 Dec;37(6):457-70. doi: 10.2165/00003088-199937060-00002. Clin Pharmacokinet. 1999. PMID: 10628897 Review.
Although ADHD has been widely studied, the use of methylphenidate in ADHD still poses a number of unresolved questions, including its pharmacodynamic characteristics (drug concentration-effect relationship) and the effect of long term treatment on the patient's psyc …
Although ADHD has been widely studied, the use of methylphenidate in ADHD still poses a number of unresolved questions, including its …
Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.
Dinis-Oliveira RJ. Dinis-Oliveira RJ. Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):11-16. doi: 10.1007/s13318-016-0362-1. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27438788 Review.
Methylphenidate (MPH) is primarily indicated for attention-deficit hyperactivity disorder and narcolepsy therapy. ...
Methylphenidate (MPH) is primarily indicated for attention-deficit hyperactivity disorder and narcolepsy therapy. ...
Attention deficit hyperactivity disorder.
Barnett R. Barnett R. Lancet. 2016 Feb 20;387(10020):737. doi: 10.1016/s0140-6736(16)00332-9. Lancet. 2016. PMID: 26913307 No abstract available.
[All you need to know about methylphenidate (and dared not ask)].
Zimmer L, Fourneret P. Zimmer L, et al. Arch Pediatr. 2018 Apr;25(3):229-235. doi: 10.1016/j.arcped.2018.01.002. Epub 2018 Mar 12. Arch Pediatr. 2018. PMID: 29544968 French.
Methylphenidate (MPH) remains the only accessible psychostimulant used in France in the attention and behavior disturbances of attention deficit disorder with or without hyperactivity (ADHD). ...
Methylphenidate (MPH) remains the only accessible psychostimulant used in France in the attention and behavior disturbances of attent
9,424 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page